Flaviviruses - Hepatitis C Virus Flashcards

1
Q

Discovery of Hepatitis C

A

Previously known as Non-A and Non-B
Discovered through infection of chimpanzees
Discovered through PCR and sequencing of infectious cloned RNA variant samples that led to implementation of EIA tests.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Epidemiology

A

Blood-borne pathogen
highest prevalence in Africa, Asia and South America
Silent epidemic - burden on the health system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Two stages of HCV infection

A
  1. Acute infection - first six months. 20% of those infected will spontaneusly clear the inection
  2. Chronic infection - After6 months
    - 80% will progress and develop Cirrhosis and liver failure.
    -5% develop hepatocellular carcinoma.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What happens to during acute infection?

A

Virons detectable in blod plasma in a few days.
-Peak viral loads observed 6-10 weeks post infection
Hepatocytes release alanine aminotransferase (ALT)
-Used as an indicator of extent of damage
-Normal range = 5-40 IU/L
-Elevation of 5-15 x normal range observed 4-12 weels post infection
Immune response delayed by several weeks
-Only detectable following ALT peak ( Once HCV-specific cytotoxic T cells are detectable an ALT peak is observed)
-Humoral responses may appear after 8 weeks p.i
-spontaneous clearance associated with strong CD4+ and CD8+ responses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What happens to during chronic infection?

A

Viral loads remain high in periphery.
ALT levels fluctuate throughout infection:
-often normal levels followed by erratic peaks.
-Indicative of progressing liver damage
-Males tend to have higher ALT levels than females.
Cellular mediated immune responses are generally ineffective:
-Humoral responses detected in 50-70% of patients.
No correlation between viral load and liver damage- reinforcing that damage is caused by active immune response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Hepatitis C Viron Components

A

50 nm in diameter
Envelope E1 and E2
Core/Nuleocaspid- surrounds genome
-Enveloped virus
-Contains positive sense, single stranded RNA molecule

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HCV genome - Components and function

A

CORE: Nucleocapsid

E1 AND E2: Envelope of virus – involved in cell entry

P7:Ion channel – needed for viral infectivity

NS2: Viral assembly and release

NS3: Helicase enzyme – unwinds RNA and DNA

NS4A: Anchors NS3 to Endoplasmic Reticulum membrane

NS4B: Membranous web essential for replication

NS5A: Genome replication

NS5B: Encodes the RNAse dependent RNA polymerase (RdRp) enzyme

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Viral Life Cycle - List stages

A

Virus enters periphery - travels to liver
1. Viral entry into cells
2. Viral translation
3. Polypeptide processing
4. Viral Replication
5. Viral assembly and release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Viral Life Cycle - Viral Entry happens in 4 stages

A
  1. Attachment to cell (hepatocyte) surface
    -Viral Envelope E2 binds to two receptors (CD81 and SRB1)
    -Binding of CD81 forces viron closer to hepatocyte tight junctions
    -SRB1 found only on hepatocytes and is normally used in lipoprotein uptake
  2. Direction to tight junctions
    -Purpose to separate neighbouring cells and maintain diffusion
    -Two types of tight junctions present: CLDN1 and Occludin
    -CLDN1 critical for viral entry
    -Occludin essential for anchoring adhesion
    -Exact mechanisms not known.
  3. Uptake via endocytosis
    -HCV fuses to cell forcing rearrangment of envelope (E1 and E2) proteins
    -Creates fusion pore
    - Endocytic vesicles formed - Clathrin-coated pits
  4. Delivery of nucleosome
    -Vesicle coat shed, delivering viral nucleocaspid (containing genetic information) into the cell cytoplasm.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Viral Life CYcle - Polypeptide Processing

A

Host signal peptidases cleave structural proteins:
- further processing of core forms nucelocaspid
-envelope proteins released - forms a non-covalent heterodimeric complex
P7 also released and folds into ion channel in the outer envelope

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Viral Life Cycle - Viral Translation

A
  • Inside cells ribosomes initiate translation of RNA sequences.
    -Viral 5’UTR contains an IRES - positions host ribsoosme at the beginning of viral sequence (riibosome attaches there)
    -Host cell then initiates protein synthesis of viral genome
    -Viral polypeptide produced.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Polypeptide procesing - role of proteases

A

Two viral proteases: NS2/NS3 and NS3/4A
NS2/NS3 zinc metalloproteases: cleaves NS2 and NS3 proteins
NS3 is a serine protease requiring cofactor NS4A
-association prevents protease degradation
-cleaves junctions between NS3/4A, NS4A/4B, NS4B/5A and NS5A/5B
Cleavage forms the replication complex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Viral Life Cycle - Viral Replication

A

-Replication driven by viral NS5B RdRp enzyme
-Essential viral component
-Structural fold consisting of a palm, finger and thumb domain:
- Palm domain contains active enzymatic site
- Feeds single stranded RNA through
- Copied in 5’ to 3’ direction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Viral Life Cycle - Viral Assembly and Release - How does the Viral particle exit the cell?

A

Viral particle exits cell via Golgi apparatus system using secretory pathway
Viral budding: Nucelocaspid is surrounded by a phospholipid bilayer with E1 and E2 anchored into the bilayer.
Viral particles become tightly bound with VLDL during assembly.
Exact process of secretion is not known.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Viral Evasion of Immune System

A

HCV thought to outpace the immune response - reaches maximum titres quickly
Sequence mutations:
- HCV exsists as a quasispecies
-NS5B RdRp lacks proof reading ability during replication
-Virus able to select escape mutants - constantly evades immune system
-Hinders vaccine development (E2 HVE1 believed to mutate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Treatment and progress: Pegylated Interferon-alpha (PEG-IFN)

A

Attached polyethylene glycol polymer chain to IFN-α extends the drug life within an individual

IFN (pegylated interferon) has anti-viral properties:
- Inhibits viral replication
- Stimulates lymphocytes

15
Q

Treatment and Progress: Ribavirin

A

Enhances effects of IFN-α
Inhibits viral NS5B RdRp
Reduces likelihood of relapse

16
Q

Treatment with OEG-IFN / Ribavirin

A

Weekly subcutaneous injections of PEG-IFN combined with 800-1400mg of ribavirin taken orally every day.

Genotype specific – differ by 20% on nucleotide sequence
- Patients with Genotype 2 and 3 (HCV type??) treated for 24 weeks
- Patients with Genotype 1 for 48 weeks

Genotype 2 and 3 = 70% are negative for virus for 6 months after treatment

Genotype 1 = 50% unresponsive to treatment

Previous option is to repeat 48 week course of treatment

Unpleasant symptoms: nausea, depression, headaches and skin inflammation
New drugs limit use of PEG-IFN.

17
Q

Treatment: Protease Blockers

A
  • Administered orally.
  • Primarily targets Genotype 1.
  • Act by blocking viral NS3/4A serine protease.
  • Unable to cleave polypeptide at NS3/4A, NS4A/4B, NS4B/5A and NS5A/B.
  • Inhibits protein processing - unable to form replication complexes
    Examples: Telaprevir and Boceprevir - must be used in conjuction with PEG-IFN and Ribavirin
    Severe side effects: anemia, rashes, fatalities
18
Q

New Treatment - 2017

A

U.S FDA approved Vosevi to treat genotypes 1 – 6 without cirrhosis

Consists of a fixed dose, containing sofosbuvir, velpatasvir and voxilaprevir - Inhibit action of protein NS5A/B

Safety and efficacy was evaluated in two Phase 3 clinical trials involving 750 adults – results showed clearing of virus in patients after 12 weeks. Most common adverse reactions in patients is headache, fatigue, diarrhoea and nausea.

19
Q

Treatment: Sofosbuvir

A

Nucleotide analogue – blocks NS5B polymerase activity.

Combined with velpatasvir to treat all genotypes

Can successfully treat without PEG-IFN

Considered essential basic medicine by WHO

400 mg once daily for duration

Undetected virus in 30 – 97 %

£35,000 for one 12 week treatment

Some countries cover 99 % of cost

20
Q

Sofosbuvir - Potential risks of treatment

A

Reactivation of HBV

Increased risk of hypoglycaemia in diabetes

Limited information around pregnancy, breast feeding and renal impairment

21
Q
A